Tert-butyl-(4-hydroxy-3-((3-(2-methylpiperidin-yl)propyl)carbamoyl)phenyl)carbamate Has Moderated Protective Activity in Astrocytes Stimulated with Amyloid Beta 1-42 and in a Scopolamine Model.

Alzheimer's disease (AD) is a neurodegenerative disease with no cure nowadays; there is no treatment either to prevent or to stop its progression. In vitro studies suggested that tert-butyl-(4-hydroxy-3-((3-(2-methylpiperidin-yl)propyl)carbamoyl)phenyl) carbamate named the compound can act as both β-secretase and an acetylcholinesterase inhibitor, preventing the amyloid beta peptide (Aβ) aggregation and the formation of fibrils (fAβ) from Aβ. This work first aimed to assess in in vitro studies to see whether the death of astrocyte cells promoted by Aβ could be prevented. Second, our work investigated the ability of the compound to inhibit amyloidogenesis using an in vivo model after scopolamine administration. The results showed that possesses a moderate protective effect in astrocytes against Aβ due to a reduction in the TNF-α and free radicals observed in cell cultures. In the in vivo studies, however, no significant effect of was observed in comparison with a galantamine model employed in rats, in which case this outcome was attributed to the bioavailability of in the brain of the rats.